Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index; 31 of the 258 sources its claims cite were checked for support.

Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism

Open access

Abstract

Steroid biosynthesis and metabolism are reflected by the serum steroid metabolome and, in even more detail, by the 24-hour urine steroid metabolome, which can provide unique insights into alterations of steroid flow and output indicative of underlying conditions. Mass spectrometry–based steroid metabolome profiling has allowed for the identification of unique multisteroid signatures associated with disorders of steroid biosynthesis and metabolism that can be used for personalized approaches to diagnosis, differential diagnosis, and prognostic prediction. Additionally, steroid metabolome analysis has been used successfully as a discovery tool, for the identification of novel steroidogenic disorders and pathways as well as revealing insights into the pathophysiology of adrenal disease. Increased availability and technological advances in mass spectrometry–based methodologies have refocused attention on steroid metabolome profiling and facilitated the development of high-throughput steroid profiling methods soon to reach clinical practice. Furthermore, steroid metabolomics, the combination of mass spectrometry–based steroid analysis with machine learning–based approaches, has facilitated the development of powerful customized diagnostic approaches. In this review, we provide a comprehensive up-to-date overview of the utility of steroid metabolome analysis for the diagnosis and management of inborn disorders of steroidogenesis and autonomous adrenal steroid excess in the context of adrenal tumors.

Overview

CoChat Summary

TL;DR

This review describes how serum and 24-hour urine steroid metabolome profiling, especially mass spectrometry–based multisteroid analysis, reveals distinct signatures of inborn steroid biosynthesis/metabolism disorders and autonomous adrenal steroid excess. It highlights steroid metabolomics—mass spectrometry plus machine learning—as a diagnostic, discovery, and prognostic tool, with an ACC malignant steroid fingerprint awaiting prospective validation.

Key findings

  • The 24-hour urine steroid metabolome measures net steroid output and can reveal underlying enzymatic deficiencies and autonomous adrenal steroid excess; urinary excretion accounts for ∼80% of steroid excretion.
  • Inborn errors show characteristic multisteroid signatures: >90% of congenital adrenal hyperplasia cases are caused by CYP21A2 deficiency, and diagnostic ratios can distinguish disorders, e.g., 5PT/PTONE is typically low (<1.5) in CYP21A2 deficiency but high (>35) in HSD3B2 deficiency.
  • In adrenal tumors, routine serum biochemistry detects steroid excess in 60% to 70% of adrenocortical carcinoma (ACC) patients, whereas urine GC-MS profiling demonstrates steroid excess in >90%; a machine learning–derived “malignant steroid fingerprint” can differentiate ACC from adrenocortical adenoma with high sensitivity and specificity.
  • Primary aldosteronism affects at least 5% of the hypertensive population, and many patients also cosecrete glucocorticoid and 11-oxygenated androgen metabolites (“Connshing syndrome”); adrenal masses are estimated in 5% of the general population, with only 5% of those being cortisol-producing adenomas manifesting as adrenal Cushing syndrome.

Methods

  • Narrative review of published literature; no primary data or new patient cohort are presented.
  • Synthesizes mass spectrometry–based steroid profiling approaches, including GC-MS for comprehensive urine steroid metabolite profiling and UHPLC-MS/MS for serum/plasma steroids and, more recently, urine steroid metabolites.
  • Focuses on steroid metabolomics—combining mass spectrometry–based steroid analysis with machine learning–based data analysis—for diagnosis, differential diagnosis, and prognostic prediction in inborn steroidogenic disorders and autonomous adrenal steroid excess.

Limitations

  • The paper states no formal limitations.
  • Evident from the text: as a review, it provides no new primary data, and some cited evidence is retrospective or preliminary; the large-scale prospective validation study of the ACC urine steroid metabolomics test has been completed but results are awaited.
  • Evident from the text: there is a paucity of published urine steroid profiling data in HSD17B3 deficiency, and no distinct steroid metabolome signature has been identified for other primary aldosteronism–causing mutations, mostly due to rarity of cases.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1210/er.2018-00262

Cites

198 of 198 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Schematic overview of steroidogenesis and corresponding urine steroid metabolites. Steroids are color-coded according to their bioactivity or commitment to a specific pathway: general precursors (yellow), mineralocorticoid precursors (light green), active mineralocorticoid (dark green), glucocorticoid precursors and inactive metabolite (light orange), active glucocorticoid (dark orange), androgen precursors (light blue), and active androgens (dark blue). Corresponding urinary metabolites are shown in yellow boxes. Arrows are labeled with the catalyzing enzyme and isoform. Essential cofactor proteins are also indicated: ADX, adrenodoxin; b5, cytochrome b5; PAPSS2, PAPS synthase 2; PRO, cytochrome P450 oxidoreductase; StAR, steroidogenic acute regulatory protein.
Figure 1. Schematic overview of steroidogenesis and corresponding urine steroid metabolites. Steroids are color-coded according to their bioactivity or commitment to a specific pathway: general precursors (yellow), mineralocorticoid precursors (light green), active mineralocorticoid (dark green), glucocorticoid precursors and inactive metabolite (light orange), active glucocorticoid (dark orange), androgen precursors (light blue), and active androgens (dark blue). Corresponding urinary metabolites are shown in yellow boxes. Arrows are labeled with the catalyzing enzyme and isoform. Essential cofactor proteins are also indicated: ADX, adrenodoxin; b5, cytochrome b5; PAPSS2, PAPS synthase 2; PRO, cytochrome P450 oxidoreductase; StAR, steroidogenic acute regulatory protein.CC BY · PubMed Central
Figure 2. (a–e) Schematic visualization of urine steroid metabolome signatures in the five variants of CAH. (a) CYP21A2, (b) CYP17A1, (c) POR, (d) CYP11B1, and (e) HSD3B2 deficiencies. The figure depicts the changes in the major urine steroid metabolites relative to the reference range median of each metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (13–28).
Figure 2. (a–e) Schematic visualization of urine steroid metabolome signatures in the five variants of CAH. (a) CYP21A2, (b) CYP17A1, (c) POR, (d) CYP11B1, and (e) HSD3B2 deficiencies. The figure depicts the changes in the major urine steroid metabolites relative to the reference range median of each metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (13–28).CC BY · PubMed Central
Figure 3. Schematic overview of the three major pathways of human androgen biosynthesis. The classic, alternative, and 11-oxygenated androgen pathways are each shown in different colors. Androgens that activate the androgen receptor are shown with broad blue arrows leading from them. Other arrows are labeled with the catalyzing enzyme and isoform where appropriate. Essential cofactor proteins are also indicated: b5, cytochrome b5; PAPSS2, PAPS synthase 2; POR, cytochrome P450 oxidoreductase.
Figure 3. Schematic overview of the three major pathways of human androgen biosynthesis. The classic, alternative, and 11-oxygenated androgen pathways are each shown in different colors. Androgens that activate the androgen receptor are shown with broad blue arrows leading from them. Other arrows are labeled with the catalyzing enzyme and isoform where appropriate. Essential cofactor proteins are also indicated: b5, cytochrome b5; PAPSS2, PAPS synthase 2; POR, cytochrome P450 oxidoreductase.CC BY · PubMed Central
Figure 4. Heat map visualization of urine steroid metabolome signatures associated with inborn disorders of androgen biosynthesis. The figure depicts the changes in the major urine steroid metabolites associated with androgen biosynthesis relative to the reference range median of each steroid metabolite and does not represent overall quantitative excretion. For explanation of the link between precursors, active steroids, and their metabolites, please see Fig. 1. Data derived from (15, 61, 62).
Figure 4. Heat map visualization of urine steroid metabolome signatures associated with inborn disorders of androgen biosynthesis. The figure depicts the changes in the major urine steroid metabolites associated with androgen biosynthesis relative to the reference range median of each steroid metabolite and does not represent overall quantitative excretion. For explanation of the link between precursors, active steroids, and their metabolites, please see Fig. 1. Data derived from (15, 61, 62).CC BY · PubMed Central
Figure 5. Heat map visualization of urine steroid metabolome signatures associated with HSD11B and H6PDH deficiencies. (a) H6PDH deficiency, (b) HSD11B1 deficiency, and (c) HSD11B2 deficiency. The figure depicts the changes in the major urine steroid metabolites relative to the reference range median of each metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (90, 92, 95–100).
Figure 5. Heat map visualization of urine steroid metabolome signatures associated with HSD11B and H6PDH deficiencies. (a) H6PDH deficiency, (b) HSD11B1 deficiency, and (c) HSD11B2 deficiency. The figure depicts the changes in the major urine steroid metabolites relative to the reference range median of each metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (90, 92, 95–100).CC BY · PubMed Central
Figure 6. Heat map visualization of urine steroid metabolome signatures associated with inborn mineralocorticoid excess. The figure depicts the changes in the major urine steroid metabolites associated with mineralocorticoid biosynthesis relative to the reference range median of each metabolite and does not represent overall quantitative excretion. For explanation of the link between precursors, active steroids, and their metabolites, please see Fig. 1. Data derived from (50, 112–124).
Figure 6. Heat map visualization of urine steroid metabolome signatures associated with inborn mineralocorticoid excess. The figure depicts the changes in the major urine steroid metabolites associated with mineralocorticoid biosynthesis relative to the reference range median of each metabolite and does not represent overall quantitative excretion. For explanation of the link between precursors, active steroids, and their metabolites, please see Fig. 1. Data derived from (50, 112–124).CC BY · PubMed Central
Figure 7. Schematic overview of the biosynthesis and downstream metabolism of the “hybrid steroids” 18-hydroxycortisol (18OHF) and 18-oxocortisol (18oxoF). Whereas 18OHF is excreted unmodified in urine, 18oxoF is primarily detected as its tetrahydro metabolite (18oxoTHF).
Figure 7. Schematic overview of the biosynthesis and downstream metabolism of the “hybrid steroids” 18-hydroxycortisol (18OHF) and 18-oxocortisol (18oxoF). Whereas 18OHF is excreted unmodified in urine, 18oxoF is primarily detected as its tetrahydro metabolite (18oxoTHF).CC BY · PubMed Central
Figure 8. Schematic visualization of urinary steroid metabolome signatures associated with disorders causing autonomous adrenal steroid excess. (a) Adrenal Cushing syndrome, (b) ACTH-dependent Cushing syndrome, (c) MACE, (d) primary aldosteronism, and (e) ACC. The figure depicts the changes in the major urinary metabolites relative to the normal median of each steroid metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (1, 148–155).
Figure 8. Schematic visualization of urinary steroid metabolome signatures associated with disorders causing autonomous adrenal steroid excess. (a) Adrenal Cushing syndrome, (b) ACTH-dependent Cushing syndrome, (c) MACE, (d) primary aldosteronism, and (e) ACC. The figure depicts the changes in the major urinary metabolites relative to the normal median of each steroid metabolite and does not represent overall quantitative excretion. Steroid metabolites are mapped onto the steroidogenic pathways leading to mineralocorticoid, glucocorticoid, and androgen biosynthesis as shown in Fig. 1. Data derived from (1, 148–155).CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 11 Not valid · 120 Not checked · 59 Own results and interpretations

88 more claims · 7 with their cited sources checked

Create a free account to see all 213 claims and to verify the 227 references still open.

See all claims — free account
  • It may state two separate claims as one. 109
  • Probably not a substantial claim. 22
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 206 references

Cited by

See all 142

Metadata

Authors
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., & Shackleton, C. H. L.
Affiliations
  • Stellenbosch University (ZA)
  • University of Birmingham (GB)
  • Birmingham Women’s and Children’s NHS Foundation Trust (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University of California, San Francisco (US)
Corresponding author
Arlt, Wiebke
Venue
Endocrine Reviews
Published
2019-07-11
Volume
40
Issue
6
Pages
1605-1625
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2960176468
Cited by
141
References
206
Citations by year
2026: 16 · 2025: 22 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 13 · 2020: 14 · 2019: 3
FWCI
11.36
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • SUNScholar (Stellenbosch University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Wellcome Trust (WT209492/Z/17/Z, WT101671AIA)
  • Medical Research Council (G1001964, MR/R017913/1)
  • Diabetes UK (18/0005782)
  • Academy of Medical Sciences UK (NAF004\1002)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
Keywords
steroid metabolome, adrenal steroidogenesis, serum steroids, adrenal tumors, personalized diagnosis, differential diagnosis, outcome prediction, machine learning
MeSH terms
Adrenal Gland Diseases, Diagnosis, Differential, Humans, Steroid Metabolism, Inborn Errors, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism. https://app.cochat.ai/papers/10.1210/er.2018-00262
The paper
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., & Shackleton, C. H. L. (2019). Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism. Endocrine Reviews. https://doi.org/10.1210/er.2018-00262

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.